Press Release – New York, NY – September 22, 2026 – Sichenzia Ross Ference Carmel LLP announced today that it represented Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a biotechnology company pioneering the development of targeted genetic medicines, in its recently priced $1.2 million registered direct offering.
The SRFC team was led by partner Marcelle Balcombe, with associate Rohini Sud.